Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of UCART19 in Advanced Lymphoid Leukemia
NCT02735083Phase 1Active, not recruiting
- Sponsor
- Servier
- Start
- Mar 2021
- Primary completion
- Sep 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of UCART19 in lymphoid leukemia, sponsored by Servier. Primary endpoint: Long-term safety of UCART19 with or without alemtuzumab up to 15 years. Started Mar 2021; status: active, not recruiting.
02
Drugs
UCART19
03
Conditions
lymphoid leukemia
Beyond the preview
Go deeper on NCT02735083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735083.